LL-37.
An innate-immune peptide used in select cases with provider discretion.
Pricing is shown after your free assessment, before you commit.
Free to start. No card required.
Reviewed by Lumora clinical team (Licensed provider network)Mixed evidenceSource: Client-approved product catalog; provider review required
Evidence, regulatory status, and fit vary by medication, formulation, route, and individual history.
Is this for you?
This is for you if
- Patients with chronic or recurrent infections (under specialist care)
- Patients with immune dysfunction not responding to standard therapy
- Patients working closely with a provider on immune restoration
This isn't for you if
Should only be used under direct provider supervision due to immune activation potential. Not appropriate during pregnancy or with autoimmune disease without specialist clearance.
LL-37
LL-37 is a naturally occurring antimicrobial peptide produced by the human immune system. It plays a role in innate immune defense and tissue repair, with broad activity against bacteria, viruses, and fungi.
Mechanism and fit.
LL-37 supports the body's innate immune response and is used selectively in physician-supervised protocols for complex or resistant cases. Because it can activate the immune system, it requires close clinical oversight.
Who this is typically for.
- Patients with chronic or recurrent infections (under specialist care)
- Patients with immune dysfunction not responding to standard therapy
- Patients working closely with a provider on immune restoration
What patients
most often ask.
Why is LL-37 used cautiously?
LL-37 strongly activates the innate immune system, which can produce noticeable effects — including inflammation, fatigue, or mast-cell responses in sensitive patients. It requires close provider supervision and conservative dosing.
Who this is typically for.
These are common fit patterns from the approved catalog. Your provider determines whether treatment is appropriate.
- <ul><li>Patients with chronic or recurrent infections (under specialist care)</li><li>Patients with immune dysfunction not responding to standard therapy</li><li>Patients working closely with a provider on immune restoration</li></ul>
How this option
is evaluated.
The plan is provider-determined after reviewing your assessment and safety factors.
- DosingDaily, typically 5 days on / 2 days off, provider-directed.
- Typical durationApproximately 4 weeks per cycle.
- Safety and eligibilityYour provider reviews contraindications, medication interactions, goals, and safety factors before prescribing.
- A licensed provider reviews your assessment before any treatment is recommended.
- You see full pricing - visit fees, medication, labs, follow-up - before you commit.
- Your plan can be adjusted, paused, or stopped based on response and safety. Your clinician is reachable - not a chatbot.
- Compounded medications are not FDA-approved and are dispensed only when prescribed by a licensed provider.
Start with
provider review.
If you are considering LL-37, the first step is a free assessment. A provider determines whether it fits your goals and medical history.
A provider determines whether treatment is clinically appropriate.